Two Medtech startups bring home CHF 20,000
18.06.2018
Congratulations to EraCal (first-in-class drugs to treat the metabolic syndrome) and Positrigo (imaging method to scan biomarkers of neurodegenerative diseases) on passing stage 2 of Venture Kick. With this success in mind, the startups will now prepare for the final stage and get with a chance to win CHF 130,000!
 EraCal
|
 |
 Positrigo
|
|
EraCal (UZH) – Medtech
EraCal aims to develop first-in-class drugs to treat the metabolic syndrome based on novel mechanism into pharmaceutical products for the world market. The approach: modulate the brain with drugs to suppress appetite allowing patients to ultimately loose body weight. At the core of the innovative technology are fifty identified appetite-suppressors, selective to food intake that do not induce neuronal side-effects and significantly outperform current anti-obesity agents in potency and in selectivity.
Positrigo BPET (ETH Zurich) - Medtech
Positron Emission Tomography (PET) is the best imaging method to scan for biomarkers of neurodegenerative diseases such as Amyloid Beta in Alzheimer's Disease. However, current scanners are both prohibitively large and expensive. Positrigo proposes to develop a cost-effective and mobile brain PET to enable scanning for diseases of the brain at significantly lower costs than currently possible, while also enabling high-throughput early diagnosis and treatment monitoring.
EraCal aims to develop first-in-class drugs to treat the metabolic syndrome based on novel mechanism into pharmaceutical products for the world market. The approach: modulate the brain with drugs to suppress appetite allowing patients to ultimately loose body weight. At the core of the innovative technology are fifty identified appetite-suppressors, selective to food intake that do not induce neuronal side-effects and significantly outperform current anti-obesity agents in potency and in selectivity.
Positrigo BPET (ETH Zurich) - Medtech
Positron Emission Tomography (PET) is the best imaging method to scan for biomarkers of neurodegenerative diseases such as Amyloid Beta in Alzheimer's Disease. However, current scanners are both prohibitively large and expensive. Positrigo proposes to develop a cost-effective and mobile brain PET to enable scanning for diseases of the brain at significantly lower costs than currently possible, while also enabling high-throughput early diagnosis and treatment monitoring.